NCT05495035 2023-03-02
Study for Safety and Efficacy of Olverembatinib Combined With APG-2575 in Children With Relapsed/Refractory Ph + ALL
Institute of Hematology & Blood Diseases Hospital, China
Phase 1 Unknown
Institute of Hematology & Blood Diseases Hospital, China
Ascentage Pharma Group Inc.
Ascentage Pharma Group Inc.